Genomics Leader Showcases Power of Next-Generation Sequencing for Detecting Salmonella and Identifying Most Common Serotypes
SAN CARLOS, Calif., July 27, 2022 /PRNewswire-PRWeb/ -- This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending and presenting at the International Association for Food Protection (IAFP) 2022 Annual Meeting. As a renowned worldwide food safety conference, the IAFP Annual Meeting educates attendees on current and emerging food safety issues, as well as the latest innovative solutions to new and recurring problems. The meeting also provides an opportunity to network with nearly 4,000 top food safety professionals from six continents.
Clear Labs Staff Scientist Andrew Lin is among notable guests leading more than 100 sessions ranging from cultivating diversity in food safety spaces to innovative ways for improving the detection and serotyping of Salmonella.
WHEN: Tuesday, August 2
2:15 p.m. - 3:45 p.m. and 5:15 p.m. - 6:15 p.m. ET
WHAT: Clear Safety™ Salmonella: Automated Targeted NGS Detection and Serotyping from Sample Enrichments
WHO: Clear Labs Staff Scientist Andrew Lin
WHERE: David L. Lawrence Convention Center
Board P2-148
1000 Fort Duquesne Blvd
Pittsburgh, PA 15222
WHY: Salmonella serotyping is an important tool to help identify strains of concern for implementation of risk-based mitigation strategies. Current methods (traditional anti-sera, DNA arrays, bead-based arrays, and whole genome sequencing) require that analysts culture and isolate Salmonella colonies prior to performing the serotyping methods.
Clear Safety Salmonella uses an automated NGS-based platform to simultaneously detect Salmonella and identify the most common serotypes from sample enrichments avoiding the need for isolating Salmonella colonies. With an analysis time of 10-12h, the Clear Safety platform can dramatically reduce the time to results.
Clear Labs is widely recognized as a pioneer in food safety. The Clear Safety platform leverages the power of its automated and intelligent next-generation sequencing platform to substitute PCR, culturing, and antigen-based tests to validate not only whether a pathogen is present or absent, but also offers other actionable insights around the detected pathogen, including the serotype or its relatedness to past occurrences.
The team will be at booth #607 in the exhibit hall and is available for meetings and questions. For more information about Clear Labs and upcoming events, visit https://www.clearlabs.com/newsroom/.
About Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex workflows for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs liberates genomics to deliver increased clarity. Clear Labs' turnkey platform accelerates outcomes and improves accuracy for detection and surveillance of infectious diseases. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.
Media Contact
Aimee Eichelberger, Superior PR, 312-952-1528, [email protected]
SOURCE Clear Labs
Share this article